Sign In
Buy LLY
$1,083.23
+18.39 (+1.73%)
At Close: Jun 03, 2026
These Stocks Are Today's Movers: Novo Nordisk, Eli Lilly, Paramount, Nvidia, and More
05:58am, Monday, 23'rd Feb 2026
Nvidia shares tick up as investors await the chip maker's fourth-quarter earnings, which likely will reveal how artificial-intelligence demand is holding up.
Novo Nordisk pitted a new weight-loss drug against Eli Lilly — and lost
05:07am, Monday, 23'rd Feb 2026
Novo Nordisk shares were under pressure on Monday as the struggling Danish pharmaceutical said a head-to-head study found a drug in development didn't cut as much weight as an Eli Lilly product.
Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly's in trial
04:53am, Monday, 23'rd Feb 2026
The drug, CagriSema, didn't achieve its primary endpoint of demonstrating non-inferiority on weight loss. In this article NVO
Novo Nordisk's obesity drug falls short against Eli Lilly's in Copenhagen trial
04:41am, Monday, 23'rd Feb 2026
Novo Nordisk said on Monday its experimental obesity drug CagriSema did not meet the primary endpoint in a trial designed to show it was non-inferior to competitor Eli Lilly's Tirzepatide in reducing
Clearstead Trust LLC Buys 1,866 Shares of Eli Lilly and Company $LLY
04:24am, Monday, 23'rd Feb 2026
Clearstead Trust LLC raised its stake in Eli Lilly and Company (NYSE: LLY) by 38.4% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commissi
Bleakley Financial Group LLC Sells 1,528 Shares of Eli Lilly and Company $LLY
05:30am, Sunday, 22'nd Feb 2026
Bleakley Financial Group LLC lowered its holdings in shares of Eli Lilly and Company (NYSE: LLY) by 4.7% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned
Eli Lilly and Company $LLY Shares Sold by Bowen Hanes & Co. Inc.
04:54am, Sunday, 22'nd Feb 2026
Bowen Hanes and Co. Inc. cut its holdings in Eli Lilly and Company (NYSE: LLY) by 8.5% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commi
Our Top 10 High Growth Dividend Stocks - February 2026
08:15am, Saturday, 21'st Feb 2026
The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rat
Dempze Nancy E Has $3.06 Million Position in Eli Lilly and Company $LLY
06:20am, Saturday, 21'st Feb 2026
Dempze Nancy E raised its holdings in Eli Lilly and Company (NYSE: LLY) by 45.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,00
Eli Lilly and Company $LLY Shares Acquired by Empirical Financial Services LLC d.b.a. Empirical Wealth Management
05:44am, Saturday, 21'st Feb 2026
Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its holdings in shares of Eli Lilly and Company (NYSE: LLY) by 6.1% in the third quarter, according to the company in its mos
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
10:00am, Friday, 20'th Feb 2026
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Eli Lilly Breaks New Ground In Crohn's Disease Treatment
07:23am, Friday, 20'th Feb 2026
Eli Lilly (LLY) reports landmark Phase 3 data for Omvoh, showing over 90% of Crohn's disease patients achieved 3-year steroid-free remission.
Prediction: Eli Lilly Stock Could Surge 45% This Year
04:30pm, Thursday, 19'th Feb 2026
Eli Lilly (LLY +0.23%) just delivered 45% revenue growth and guided toward $83 billion in 2026 sales. With blockbuster obesity drugs, multiple growth catalysts, and analysts targeting $1,500, this hea
3 Stocks to Buy and Hold for 2026 and Beyond
12:15pm, Thursday, 19'th Feb 2026
AbbVie is a Dividend King, poised for strong growth with Rinvoq and Skyrizi. Eli Lilly has taken control of the obesity drug market, with major possibilities ahead.
Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)
12:15pm, Thursday, 19'th Feb 2026
Landmark VIVID-2 data showed more than 90% of patients who achieved steroid-free remission at one year maintained steroid-free control through three years Additional new data revealed exceptionally
